Sickle Cell DiseaseNCT02785848
Identifying Barriers and Strategies to Support Self-efficacy for Medication Adherence With Text Messaging
An observational study of Sickle Cell Disease, run by Vanderbilt University at 1 site in United States.
Trial summary
The investigators will explore barriers to improving self-efficacy, or the ability to feel in control of their disease, and medication adherence with text messaging through surveys and interviews with adolescents and adults with SCD cared for at the Vanderbilt Meharry Center of Excellence (VMCE) in Sickle Cell Disease… Read more about this study
- Who is it for?
- Ages 12 to 70 years
- Conditions the study is for
- Sickle Cell Disease
- What is being tested?
- Interviews and Surveys
- How many people
- 70 participants
- Where
- 1 siteUnited States
- Study dates
- May 2016to Sep 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 70 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The investigators will assess barriers to self-efficacy and medication adherence in the adolescents and adults with sickle cell disease (SCD), asthma, or both, who take daily medications such as hydroxyurea, asthma, or both, have access to mobile phones and/or computers and receive care at the VUMC/Matthew Walker clinic.
Who may be able to join
- Receiving care at the VUMC/Matthew Walker clinic
- Diagnosed with SCD, asthma, or both
- Currently taking daily medications for SCD, such as hydroxyurea, asthma, or both
- Having access to a mobile telephone and/or computer
- Age 12-70 years
Who cannot join
- 1. Unable to perform interviews or surveys
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Identifying Patient-centered Barriers and Preferred Strategies to Support Self-efficacy for Medication Adherence With Two-way Text Messaging
The investigators will explore barriers to improving self-efficacy, or the ability to feel in control of their disease, and medication adherence with text messaging through surveys and interviews with adolescents and adults with SCD cared for at the Vanderbilt Meharry Center of Excellence (VMCE) in Sickle Cell Disease (SCD). The investigators will identify preferences to improve and sustain adherence to daily medication through selection of investigator-proposed or patient-generated text messaging strategies. Finally, the investigators will fill in the literature gaps by describing barriers to self-efficacy and medication adherence among adults with SCD as well as adolescents with SCD who are transitioning to adult care.
- Conditions
- Sickle Cell Disease
- Being tested
- Interviews and Surveys
- Medical subject headings
- Anemia, Sickle Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Interviews and SurveysOther
The investigators will perform semi-structured interviews and surveys on this cohort
| Study group | Role | What they receive |
|---|---|---|
| Asthma and/or Sickle Cell Anemia | The investigators will examine patients with sickle cell disease, asthma, or both who are aged 12-70 years who take daily medications. Receives: Other: Interviews and Surveys |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients with barriers to medication adherence
High cost, forgetting, side effects, access to medications
Measured: 1 year
Secondary outcomes (1)
Number of patients that prefer a tailored text messaging technological solution
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2016 (estimated)
- Study startMay 2016
- Primary completionMay 2022
- Study completionSep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sickle Cell DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vanderbilt University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Robert M Cronin, MD, MS, Vanderbilt University
- Investigators
- Robert Cronin, MD, MS, Principal investigator, Vanderbilt University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02785848
- Sponsor's protocol ID
- 160750
- Status last verified
- Sep 2026
- First submitted
- 25 May 2016
- Last updated
- 23 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identifying Patient-centered Barriers and Preferred Strategies to Support Self-efficacy for Medication Adherence With Two-way Text Messaging
- ClinicalTrials.gov ID
- NCT02785848
- Acronym / sponsor ID
- 160750
- Conditions
- Sickle Cell Disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Vanderbilt UniversityUniversity, hospital or other
- Study start
- May 2016
- Primary completion
- May 2022 (actual)
- Study completion
- Sep 2026 (actual)
- First posted
- 30 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators will explore barriers to improving self-efficacy, or the ability to feel in control of their disease, and medication adherence with text messaging through surveys and interviews with adolescents and adults with SCD cared for at the Vanderbilt Meharry Center of Excellence (VMCE) in Sickle Cell Disease (SCD). The investigators will identify preferences to improve and sustain adherence to daily medication through selection of investigator-proposed or patient-generated text messaging strategies. Finally, the investigators will fill in the literature gaps by describing barriers to self-efficacy and medication adherence among adults with SCD as well as adolescents with SCD who are transitioning to adult care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Asthma and/or Sickle Cell Anemia | – | Other: Interviews and SurveysThe investigators will examine patients with sickle cell disease, asthma, or both who are aged 12-70 years who take daily medications. |
Who may qualify
- Ages
- 12 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The investigators will assess barriers to self-efficacy and medication adherence in the adolescents and adults with sickle cell disease (SCD), asthma, or both, who take daily medications such as hydroxyurea, asthma, or both, have access to mobile phones and/or computers and receive care at the VUMC/Matthew Walker clinic.
Key inclusion criteria (5 listed)
- Receiving care at the VUMC/Matthew Walker clinic
- Diagnosed with SCD, asthma, or both
- Currently taking daily medications for SCD, such as hydroxyurea, asthma, or both
- Having access to a mobile telephone and/or computer
- Age 12-70 years
Key exclusion criteria (1 listed)
- 1. Unable to perform interviews or surveys
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Interviews and SurveysThe investigators will perform semi-structured interviews and surveys on this cohort | Other | Asthma and/or Sickle Cell Anemia |
Primary outcome
Number of patients with barriers to medication adherence
Time frame: 1 year
High cost, forgetting, side effects, access to medications
1 secondary outcome
Number of patients that prefer a tailored text messaging technological solution
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2026.
Related trials for Sickle Cell Disease
Active, not recruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Sickle Cell Disease, Hemolytic Anemia
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
RecruitingPhase 1
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Sickle Cell Disorders, Sickle Cell Disease
RecruitingPhase 4
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Not yet recruitingPhase 1
Buprenorphine for the Management of Pain in Children With Sickle Cell Disease
Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert Cronin, MD, MS principal investigator
Vanderbilt University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sickle Cell Disease, run by Vanderbilt University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients with barriers to medication adherence (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.